Document text
Principal Investigator: Pamina Mae Gorbach
Organization: UNIVERSITY OF CALIFORNIA LOS ANGELES
Fiscal Year: 2021
Award: $400,898
Funding agency: National Institute on Drug Abuse
ABSTRACT
In response to RFA-DA-17-019 we propose to establish a Coordinating Center for the NIDA Cohorts entitled
“C3NPO” *
to manage and stimulate use of the data generated
to address high priority research on HIV/AIDS
in the context of substance abuse. Our focus is cutting-edge science powered by the cohorts' combined
sample size of approximately 12,500 participants. We bring together a team of researchers with global
leadership in substance use, HIV prevention, clinical science and co-morbidities, immunology, modeling, and
bioethics to work with NIDA program scientists to stimulate the highest impact science across NIDA-funded
cohorts that have compiled unique repositories of varied and rich data. Our proposal uniquely combines
academic and professional research management expertise that will stimulate, manage, and support scientific
collaboration. We will enable internal and external investigators to cultivate the data from these cohorts in new
and innovative scientific directions. Our bioinformatics capacity is uniquely strong in the area of specimen
management, having developed the industry gold standard software that will greatly facilitate sharing of
specimens across the cohorts. Our leadership bridges NIDA's interests with the perspectives and concerns of
the cohorts by having a cohort PI/research scientist (Pamina Gorbach, University of California, Los Angeles)
partnered with an experienced HIV network bioinformatics management leader (Suzanne Siminski, Frontier
Science & Technology Research Foundation (FSTRF). We will leverage other funded research initiatives
though our External Scientific Advisory Board (ESAB) such as NIDA-supported efforts to harmonize measures
for substance use research and combine that with data linking strategies. We have the endorsement of all
cohort PIs that Consortium leadership is best led from another cohort PI to enhance team science and support
for our team as the leaders. The collaborative character of this proposing team offers the potential for new
developments in bioinformatics techniques that allow integration of diverse and ever more massive sets of
behavioral, clinical, and laboratory data for use by cohort and outside researchers. Thus, our proposal will
address NIDA's 2016-2020 Strategic Plan priority focus areas and cross-cutting themes
(https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan) by leveraging technology, driving
innovation, promoting collaboration, and encouraging data and resource sharing. The strategy will develop
infrastructure that allows cross-disciplinary, large-scale analyses leading to the highest impact HIV science on
substance use.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><AIDS prevention><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adherence><Administrative Supplement><Affect><Appointment><Area><Attitude><Baltimore><Behavior><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 testing><COVID-19 vaccination><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 testing><COVID19 vaccination><COVID19 virus><CV-19><CV19><California><Caring><Chicago><CoV-2><CoV2><Collection><Communities><Competence><Consequentialism><Counseling><Data><Disease><Disorder><Drug usage><Drug user><Drugs><Ethnic Origin><Ethnicity><Food><Food or Food Product><Frequencies><Funding><Funding Opportunities><HIV><HIV Infections><HIV Prevention><HIV/AIDS prevention><HTLV-III Infections><HTLV-III-LAV Infections><Health><Heart><Housing><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Imprisonment><Individual><Infrastructure><Interruption><LAV-HTLV-III><Link><Location><Los Angeles><Lymphadenopathy-Associated Virus><Measures><Mediating><Medical><Medical Records><Medication><Mental Health><Mental Hygiene><NIDA><NIH Program Announcements><National Institute of Drug Abuse><National Institute on Drug Abuse><Opiates><Opioid><Outcome><PWUD><Participant><Patient Self-Report><Pattern><Persons><Pharmaceutic Preparations><Pharmaceutical Preparations><Population><PrEP><Program Announcement><Psychological Health><Race><Racial Group><Racial Stocks><Recovery><Reporting><Research><Risk><Risk Factors><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 testing><SARS-CoV-2 vaccination><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Self-Report><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome related corona virus 2><Severities><Smoking><Specific qualifier value><Specified><Structure><Substance Use Disorder><Survey Instrument><Surveys><Symptoms><Syndrome><Technology><Time><Tobacco><Universities><Vaccination><Vaccines><Virus-HIV><Vulnerable Populations><Wuhan coronavirus><accept vaccination><accept vaccine><anti-retroviral therapy><anti-retroviral treatment><antiretroviral therapy><antiretroviral treatment><base><behavior test><behavioral test><cannabis vaping><cohort><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 testing><coronavirus disease 2019 vaccination><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><data harmonization><design><designing><drug use><drug/agent><experience><frontier><hCoV19><harmonized data><hesitant to vaccination><high risk><incarcerated><incarceration><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interest><intimate partner violence><licit opioid><marijuana vaping><nCoV2><novel><opiate medication><opiate use disorder><opioid medication><opioid use disorder><pandemic><pandemic disease><people who use drugs><people who use illicit drugs><persons who use drugs><pre-exposure prophylaxis><prescribed opiate><prescribed opioid><prescription opiate><prescription opioid><protective behavior><public health emergency><response><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 testing><social><stimulant use><substance use><substance use treatment><substance using><uptake><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination acceptability><vaccination acceptance><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination confidence><vaccination hesitancy><vaccination uptake><vaccination willingness><vaccine acceptability><vaccine acceptance><vaccine confidence><vaccine hesitancy><vaccine hesitant><vaccine uptake><vaccine willingness><vaping><vulnerable group>